Is Rydapt used with chemotherapy for AML?

Is Rydapt (midostaurin) ever given with chemotherapy for AML?

Rydapt (midostaurin) is used together with standard induction and consolidation chemotherapy for adults with newly diagnosed acute myeloid leukemia (AML) that has a specific mutation—FLT3—when that mutation is present.[1]

When does midostaurin get added during AML treatment?

Rydapt is taken in combination with chemotherapy as part of the AML treatment course, not as a stand-alone therapy.[1] (The key point for patients and clinicians is that it’s paired with chemotherapy for FLT3-mutated newly diagnosed AML.)

Does Rydapt work for all AML, or only certain patients?

Rydapt is specifically indicated for FLT3-mutated AML. If a patient’s AML does not have the relevant FLT3 mutation, Rydapt is not the treatment referenced for combination use with chemotherapy.[1]

What’s the best next step if someone is deciding whether to add Rydapt?

The practical step is confirming whether the AML is FLT3-mutated, since the combination-with-chemotherapy use depends on that biomarker.[1]

Source

[1] https://www.drugpatentwatch.com/